Teismann, Peter

Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease

Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience

Neuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and Treatments

Cited by 1,183

D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease

Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation

Parkinson's Disease Mechanisms and TreatmentsMitochondrial Function and Pathology

Cited by 497

The role of glial cells in Parkinsonʼs disease

Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 326

S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

Sathe, K., Maetzler, W., Lang, J. D., Mounsey, R. B., Fleckenstein, C., Martin, H. L., Schulte, C., Mustafa, S., Synofzik, M., Vukovic, Z., et al. (2012) · Brain

Parkinson's Disease Mechanisms and TreatmentsS100 Proteins and Annexins

Cited by 202

Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity

Teismann, P., Sathe, K., Bierhaus, A., Leng, L., Martin, H. L., Bucala, R., Weigle, B., Nawroth, P. P., & Schulz, J. B. (2012) · Neurobiology of Aging

Advanced Glycation End Products researchParkinson's Disease Mechanisms and Treatments

Cited by 75